ABSTRACT

Objectives:

To evaluate the post-treatment upto fourth-year kinetics of alpha-fetoprotein (AFP) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral (DAA) drugs.

Materials and Methods:

In this retrospective, single-center study, 182 patients (124 female, 58 male) with CHC treated with DAA were included in the study. Biochemistry and AFP were recruited from the hospital database. The data at pre-treatment, 3^rd and 48^th month after the end of treatment were evaluated.

Results:

Of the 182 patients, mean age was 58±12 (28-76), and forty-nine (27%) had cirrhosis. At month 3, the average decline of AFP was 35.6% (0.4-97.0). Early decline of AFP <8.7% was found to be a predictor for HCC development. Mean AFP was 7.7±9.2 ng/mL at pre-treatment and 3.8±2.7 at third month (p<0.001). The decline persisted at 48^th month (3.6±2.4 ng/mL).

Conclusion:

Early decline of AFP and persistence at fourth-year after DAA treatment was observed, except five cases developing HCC. Inadequate decline in AFP level found to be a possible predictor for HCC development. However, these results needs to be confirmed in large-scale multicenter cohorts. This study highlights the importance of AFP response to DAA treatment in identifying HCC risk, especially in patients with cirrhosis.

Keywords:

Alpha-fetoprotein, chronic hepatitis C, direct-acting antivirals, hepatocellular carcinoma

Introduction

Chronic hepatitis C (CHC) is still a global cause of cirrhosis and hepatocellular carcinoma (HCC) (1). Alpha-fetoprotein (AFP), an onco-fetal glycoprotein with 59 amino acids and a half-life of five days may have mild elevations in CHC regardless of HCC (2). Early identification of HCC and early tumor stage determines the prognosis, thus close monitorization and evaluating AFP response are essential factors (3,4).

We aimed to examine the change in AFP levels following direct-acting antivirals (DAA) treatment and to determine the correlation of AFP change with biochemical parameters, aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis index based on four factors (FIB-4) scores.

Materials and Methods

We conducted a retrospective study of consecutive adult patients (older than 18 years) with CHC who received 12 or 24 weeks of DAA treatment between January 2015 and January 2017 in a tertiary hepatology clinic. Patients with CHC who received DAAs and under follow-up for at least 48 months. Patients with co-infection and who had HCC within 12 months of DAA treatment were excluded. Medical files were reviewed and the following data were recorded; 1) demographics, 2) co-morbidities, 3), underlying cirrhosis, 4) laboratory values including alanine aminotransferase (ALT), aspartate aminotransferase (AST), AFP, hepatitis C virus-RNA (HCV-RNA), HCV genotype (GT), and platelet (Plt) count, and hepato-biliary ultrasound. The treatment criteria were defined as CHC patients with Ishak fibrosis score ≥2 and /or hepatic activity score ≥2, patients with cirrhosis based on the reimbursement criteria of the Turkish Ministry of Health as of January 2015. The DAA treatment regimens included sofosbuvir + ledipasvi, ombitasvir + paritaprevir + ritonavir + dasabuvir, sofosbuvir and additional ribavirin in cirrhotic patients. The sustained viral response (SVR) was defined as the HCV-RNA negativity at the 3^rd month of end-of-treatment (EOT). The SVR was defined as the HCV-RNA negativity at the 3^rd month of EOT. The diagnosis of cirrhosis was based on biopsy, signs of portal hypertension, imaging and laboratory tests including ultrasound, transaminases, albumin, Plt, international normalized ratio and bilirubin.

The non-invasive fibrosis markers FIB4 score [(age x AST)/(Plt x √ALT)] and APRI score [(AST/upper limit of AST) X 100/Plt)] were calculated. FIB4 <1.45 indicates the absence of cirrhosis (with 90% negative predictive value for fibrosis), while the score between 1.45-3.25 is regarded as inconclusive and results >3.25 indicate cirrhosis (65% positive predictive value for advanced fibrosis). APRI <0.5 normal and ≥1.5 regarded likely as cirrhosis (5,6).

The study was approved by Ethics Committee İstanbul Medeniyet University, Göztepe Training and Research Hospital (approval number: 124, date: 17.05.2018).

Statistical Analysis

Statistical evaluation was done with SPSS v20 (IBM, Chicago). Numerical data are given as mean ± standard deviation (SD). The normality of distribution control was done by Kolmogorov-Smirnov. Categorical data were analyzed by chi-square or Fisher’s exact tests. Student’s t-test or Mann-Whitney U test was used for comparison of numeric values of two groups, and ANOVA or Kruskal-Wallis was used for more than 2 categories depending on normality of distribution. The cut-off point was calculated based on a receiver operator characteristic curve analysis. The results were given as mean ± SD. The p<0.05 was considered as the level of statistical significance.

Results

The study group consisted of 182 cases with HCV, mean age 58±12 (range: 28-76), 124 (68.1%) female, and all caucasian. SVR in the 12^thweek after the EOT was achieved in 98.4% of cases treated with DAAs. HCC developed in five patients with cirrhosis during a follow-up of 4 years. Pre-treatment (PreT) mean AFP level was 6.4±6.9 ng/mL in non-cirrhotic (n=133) and 11.1±13.1 ng/mL in cirrhotic cases (n=49) (p=0.021). Also, AFP level over 10 ng/mL was in 32.7% of the cirrhotic and 13.5% in non-cirrhotic patients. Initial, 3^rd and 48^th month AFP values were 7.5±9.2 ng/mL, 3.8±2.6 ng/mL, and 3.6±2.4 ng/mL, respectively (p=0.032).

The mean decline in AFP at the 3^rd month compared to PreT was 33.3%±20.0% and 44.0%±22.0% for cirrhotic and non-cirrhotic cases, respectively (p=0.005). AFP level decreased in 159 (87.4%), increased in 15 (8.2%), and didn’t change in 8 (4.4%) cases. The demographic and laboratory values are shown in Table 1.

Table 1

Genotype distribution was as follows: GT1a 22 (12%), GT1b 148 (82%), GT2 4 (2%), GT3 4 (2%), GT4 4 (2%). Distribution of DAAs was sofosbuvir + ledipasvir (n=84), ombitasvir + paritaprevir + ritonavir + dasabuvir (PROD) (n=91), sofosbuvir (n=7), and additional ribavirin (n=67).

One non-cirrhotic case was non-responder and two cases relapsed (one cirrhotic). Five cirrhotic cases (4 responders and 1 relapser) developed HCC within 48 months of follow-up.

The cut-off for predicting HCC development in cirrhotic cases was 8.7% decline in AFP in our cohort (area under the curve 0.914, p=0.003, 0.818-1.000). Five cases developing HCC were female (n=3), GT1a (n=2), GT1b (n=3), non-responder (n=1), relapser (n=1), sofosbuvir based protocol (n=4), interferon-experienced (n=2), asthma (n=1), diabetes mellitus (n=3), hypertension (n=3), and chronic kidney disease (n=2).

Discussion

The pre-treatment level of AFP was found in a wide as 1-73 ng/mL in cirrhotic and 1-45 ng/mL in non-cirrhotic cases, with no evidence of HCC. The baseline AFP over 5.5 ng/mL was reported as 10%-48.2% of CHC patients in numerous studies (7). In our study AFP over 5.5 ng/mL was in 45.1% of cases. The AFP level was correlated with serum uric acid, steatosis, fibrosis, and low albumin levels (7).

In our study, the baseline AFP was not different between genotypes (p=0.110), CKD (p=0.149), diabetes mellitus (p=0.396), gender (p=0.343), but significantly higher in cirrhotic compared to non-cirrhotic (p=0.002). HCC cases had insignificantly higher baseline values of age, AFP, AST, ALT, HCV-RNA, Plt, APRI, and FIB-4 scores compared to the non-HCC group. In a study, males had lower post-treatment AFP, but still had the risk of HCC compared to females and the cut-off was reported lower as 3.5 ng/mL (8). Rapid decline of AFP in CHC during treatment may be due to subsiding low-level inflammation in the liver, thus AFP may also be an acute phase reactant to ongoing liver inflammation.

In the recent decade, DAAs are increasingly efficacious in treating and raising the disease-related quality of life in CHC (9). One of the new emerging problems is the possible onset of post-treatment HCC, especially in patients with higher fibrosis (9,10). In our cohort, 2.74% of cases developed HCC. The HCC arising after DAA treatment is reported to have an aggressive prognosis (11). AFP normalization is found to be related to better prognosis (12,13). Even in patients without cirrhosis, Fib-4 scores ≥3.25 should be under follow-up for HCC (14). Older age is also another risk factor in SVR positive cases for HCC development (15). All five cases of HCC in our group were over 60 years old. The change of AFP in the 3^rdmonth was 1.8% and 38.0% for cirrhotic with and without HCC, respectively (p=0.003). Serum AFP levels in pre-treatment and 48^th month for each five HCC cases were changed 25 to 3,661 ng/mL, 9 to 917 ng/mL, 8 to 514 ng/mL, 18 to 21 ng/mL and 7 to 9 mg/dL.

In a study, AFP elevated 22.6% of cases and decreased in 77.4% after DAA treatment (16). A similar decline was also shown in interferon-alpha-based treatments (17,18). Lack of decrease in AFP was found to be a risk factor for HCC (19,20). Our study is compatible with this finding and additionally, a cut-off value for insufficient AFP decrease as 8.7% was a risk factor tor HCC development in cirrhotic and older patients.

In patients with CKD, AFP serum level was reported to have different kinetics (21). In our data, pre-treatment mean level (2.8±1.6 ng/mL) decreased to post-treatment (2.3±1.1 ng/mL) in CKD cases. AFP values were lower in CKD cases both pre- and post-treatment (p=0.000, p=0.032, respectively).

Study Limitations

The limitations of this study were the small number of HCC patients, retrospective pattern, lack of pre-treatment advanced imaging (22), genotype dominance of 1b, one ethnic group, the strength of the study was the availability of paired laboratory results of same laboratory standards and long-term surveillance for all cases.

Conclusion

In this CHC cohort DAAs resulted as 98,4% SVR at 12^th week. The average change of AFP level was at 35% decline in all cases. In long-term surveillance, five cirrhotic cases with insufficient AFP response to treatment had developed HCC. Thus, despite to necessity for large-scale and multicenter data, insufficient AFP response to DAA treatment may be an alert for close monitorization of HCC.

Ethics Committee Approval: The study was approved by Ethics Committee İstanbul Medeniyet University, Göztepe Training and Research Hospital (approval number: 124, date: 17.05.2018).

Informed Consent: Since our study was retrospective, informed consent was waived.

Peer-review: Externally peer-reviewed.

Authorship Contributions: Concept: E.Ş., B.D., C.U., Design: E.Ş., B.D., C.U., F.E., Supervision: B.E.Ş., Y.Ç., Data Collection or Processing: B.D., C.U., B.E.Ş., Analysis or Interpretation: S.Y., Y.Ç., C.U., B.D., Literature Search: B.D., C.U., Writing: C.U., S.Y., B.D., Critical Review: S.Y., F.E., E.Ş., B.E.Ş.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial disclosure: The authors declare no financial support.

References

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380.

Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337

He C, Peng W, Liu X, Li C, Li X, Wen TF. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2019 Aug;98(31):e16557.

Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016;9:172-179.

Yosry A, Fouad R, Alem SA, Elsharkawy A, El-Sayed M, Asem N, Hassan E, Ismail A, Esmat G. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol. 2016;17:78-83.

Gamil M, Alboraie M, El-Sayed M, Elsharkawy A, Asem N, Elbaz T, Mohey M, Abbas B, Mehrez M, Esmat G. Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. J Med Virol. 2018;90:1080-1086.

Chen CH, Lin ST, Kuo CL, Nien CK. Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma. Hepatogastroenterology. 2008;55:1423-1427.

Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Nakamura Y, Hirooka M, Abe M, Hiasa Y. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J Med Virol. 2020.

Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2018;47:516-525.

Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017;47:1021-1031.

El Fayoumie M, Abdelhady M, Gawish A, Hantour U, Abdelkhaleek I, Abdelraheem M, Alsawak A, Alwassief A, Elbahrawy A. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest Tumors. 2020;7:50-60.

Huynh T, Hu KQ. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma. Front Med. 2019;13:658-666.

Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G, Durazo FA, El-Kabany MM, Han SB, Saab S. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;28;5:43-49.

Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Post-treatment levels of a-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017;47:1021-1031.

Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212.

Fouad R, Elsharkawy A, Abdel Alem S, El Kassas M, Alboraie M, Sweedy A, Afify S, Abdellatif Z, Khairy M, Esmat G. Clinical impact of serum a-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol. 2019;31:1129-1134.

Kasztelan-Szczerbińska B, Słomka M, Celiński K, Szczerbiński M. Impact of interferon-alpha therapy on the serum level of alpha-fetoprotein in patients with chronic viral hepatitis. Rocz Akad Med Bialymst. 2003;48:74-77.

Tachi Y, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H. a-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. J Gastroenterol Hepatol. 2016;31:1001-1008.

Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell’Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D’Offizi G, Gasbarrini A, De Santis A, Angelico M. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2018;25:1493-1500.

Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 2018;38(Suppl1):139-145.

Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007;26:1187-1194.

Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma